drugset / Trial / NCT06548139
Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
Phase 2
Not yet recruiting
120 enrolled
Changchun BCHT Biotechnology Co.
Anning City First People's Hospital · collabBeijing Contreke Statistical Technology Co., LTD · collabMilitary Science Zhengyuan (Beijing) Pharmaceutical Research Co., LTD · collabThe First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine · collabYunnan Central Hospital · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
To evaluate the antibody neutralization activity and safety of rabies mAb CBB 1 combination vaccine used in healthy people
Timeline
- Start
- 2024-07-31
- Primary completion
- 2025-05-31
- Completion
- 2025-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBB 1 | Monoclonal antibody | 50 ug/kg | Intramuscular |
| Subject | CBB 1 | Monoclonal antibody | 100 ug/kg | Intramuscular |
| Comparator | Rabies Human Immunoglobulin | Protein / enzyme biologic | 20 iu/kg | Intramuscular |
| Background | Lyophilized rabies vaccine for human use (Vero cells) | Vaccine | — | — |